Sugi Predict

Sugi Predict / Compounds / SCHEMBL1343403

SCHEMBL1343403

SCHEMBL1343403

CC(C)(C)OC(=O)N[C@@H](CCO)C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 11/20 0.47
▸ CTSS P25774 7/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ CTSL P07711 1/20 0.43
▸ CTSB P07858 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.42
▸ CYP2D6 P10635 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ P2RY2 P41231 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24214307 1.00 CTSK (0.47) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL6296123 1.00 CTSK (0.47) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL1837430 0.91 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL13640177 0.91 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL939021 0.91 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL16502401 0.90 CTSK (0.43) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL613038 0.90 CTSK (0.51) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL5033246 0.90 CTSK (0.51) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL19695765 0.90 CTSK (0.51) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL613037 0.90 CTSK (0.51) CTSKCTSSCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4725560-A2 ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2026-04-15 — — EP disclosed
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 — — US disclosed
US-20250241926-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2025-07-31 — — US disclosed
EP-4419207-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 — — EP disclosed
EP-4534524-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PeptiDream Inc. (JP) 2025-04-09 — — EP disclosed
US-20250099600-A1 Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-03-27 — — US disclosed
US-12144865-B2 Antibody drug conjugates with enzymatically cleavable groups BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2024-11-19 — — US disclosed
CN-118632841-A Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-09-10 — — CN disclosed
EP-4419207-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2024-08-28 — — EP disclosed
EP-4406606-A2 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G Bayer Pharma Aktiengesellschaft (DE) 2024-07-31 — — EP disclosed
EP-1964577-A2 Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase Chroma Therapeutics Limited (GB) 2008-09-03 — — EP disclosed
EP-1964578-A2 Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase Chroma Therapeutics Limited (GB) 2008-09-03 — — EP disclosed
EP-1877098-A2 ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE Chroma Therapeutics Limited (GB) 2008-01-16 — — EP disclosed
EP-1828109-A2 GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH UCL Business PLC (GB) 2007-09-05 — — EP disclosed
WO-2006117567-A2 ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE CHROMA THERAPEUTICS LTD (GB) 2006-11-09 — — WO disclosed
WO-2006051314-A2 GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH UCL BUSINESS PLC (GB) 2006-05-18 — — WO disclosed
US-5972975-A Substituted 2-aminopyridines as inhibitors of nitric oxide synthase MERCK & CO., INC. (US) 1999-10-26 — — US disclosed
EP-0646596-B1 Nucleic acid binding oligomers having C-branches for therapy and diagnosis BAYER AG (DE) 1999-05-26 — — EP disclosed
US-5849893-A Nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics BAYER AKTIENGESELLSCHAFT (DE) 1998-12-15 — — US disclosed
EP-0646596-A1 Nucleic acid binding oligomers having C-branches for therapy and diagnosis BAYER AG (DE) 1995-04-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 CTSK 4661/4885CTSS 4022/4885CYP1A2 2870/4885
US-20250241926-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER NQO1, VHL, SDHA CTSK 1668/4885CTSS 1842/4885CYP1A2 49/4885
US-20250099600-A1 Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates KIF18B, KIF18A, KIF5B CTSK 2951/4885CTSS 3481/4885CYP1A2 4380/4885
US-12144865-B2 Antibody drug conjugates with enzymatically cleavable groups KIFC1, KIF2C, KIF5B CTSK 1510/4885CTSS 976/4885CYP1A2 3210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.